BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 has a unique binding profile and selectively binds to and eliminates soluble, toxic amyloid-beta aggregates (protofibrils) that are thought to
TauRx : Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-moderate Alzheimer’s Disease
TauRx has reportedunexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease. These results showed that, even at
AC Immune will receive €27.6M (CHF 30M) from big pharma Eli Lilly as it begins a phase I trial of its first-in-class Alzheimer’s disease drug. This is the first milestone payment in a deal worth up to €1.6B (CHF 1.7B), which
AXON Neuroscience, an industry leading, clinical stage biotech at the forefront of treatment and prevention of Alzheimer's disease, has announced the results of the Phase II trial for AADvac1, its first-in-class vaccine to slow down the progression of Alzheimer's Disease.